SciSparc (Nasdaq: SPRC) is a CNS-focused biopharmaceutical company, primarily cannabinoid-based, that is psychedelic-adjacent through an ongoing collaboration with Clearmind Medicine on novel psychedelic-derived therapeutics. The joint programs pair SciSparc's proprietary CannAmide (PEA) with compounds such as MDMA, ibogaine and ketamine, and a majority-owned subsidiary is pursuing a non-hallucinogenic MEAI-PEA neuroplastogen for major depressive disorder. The work spans addiction and metabolic indications and remains early-stage.
SciSparc News 16 articles
- SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
- SciSparc unit NeuroThera and Clearmind file Hong Kong patent for combination depression therapy
- SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
- SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
- SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
- SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
- SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
- SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
- SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
- Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
- SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
- SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
- SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
- SciSparc and Clearmind Collaboration Yields Another Patent Application for Proprietary Psychedelic Combination
- Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
- Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration